NCT06277024 2024-02-26A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma PatientsFujian Medical UniversityPhase NA Recruiting50 enrolled